Related Experiment Video
Updated: Jun 13, 2026
Murine Prostate Micro-dissection and Surgical Castration
Published on: May 11, 2016
Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer
Irene Zamora1, Michael R Freeman2,3, Ignacio J Encío1,4
1Department of Health Science, Public University of Navarre, 31008 Pamplona, Spain.
Abstract:
Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer (PC) that commonly emerges through a transdifferentiation process from prostate adenocarcinoma and evades conventional therapies. Extensive molecular research has revealed factors that drive lineage plasticity, uncovering novel therapeutic targets to be explored. A diverse array of targeting agents is currently under evaluation in pre-clinical and clinical studies with promising results in suppressing or reversing the neuroendocrine phenotype and inhibiting tumor growth and metastasis. This new knowledge has the potential to contribute to the development of novel therapeutic approaches that may enhance the clinical management and prognosis of this lethal disease. In the present review, we discuss molecular players involved in the neuroendocrine phenotype, and we explore therapeutic strategies that are currently under investigation for NEPC.
Insights
Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer. Research reveals molecular drivers and new therapies targeting NEPC
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Neuroendocrine prostate cancer (NEPC) is an aggressive prostate cancer (PC) subtype.
- NEPC often arises from prostate adenocarcinoma via transdifferentiation, evading standard treatments.
- Molecular research is identifying key factors driving lineage plasticity in NEPC.
Purpose of the Study:
- To review molecular mechanisms underlying the neuroendocrine phenotype in prostate cancer.
- To explore emerging therapeutic strategies targeting NEPC.
- To highlight potential advancements in managing this lethal disease.
Main Methods:
- Literature review of molecular research on NEPC.
- Analysis of pre-clinical and clinical studies on NEPC targeting agents.
- Discussion of therapeutic strategies under investigation.
Main Results:
- Factors driving lineage plasticity in NEPC have been identified.
- Novel therapeutic targets for NEPC are emerging from molecular research.
- Targeting agents show promise in pre-clinical and clinical studies.
Conclusions:
- Understanding NEPC's molecular drivers is crucial for developing new treatments.
- Emerging therapies offer potential for improved clinical management and prognosis.
- Continued research into NEPC is vital for combating this aggressive cancer.
More Related Videos
10:38Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture
Published on: November 22, 2019
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
